Paul Sekhri - COMPUGEN Chairman of the Board

<div class='circular--portrait' style='background:#82ADFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>CO</div>
CGEN -- Israel Stock  

ILA 6,037  487.00  8.77%

Mr. Paul Jai Sekhri was appointed Director and Chairman of the Board at Compugen Ltd. effective October 2, 2017. His work experience includes the following roles Chairman of the Board of Supervisory Directors of Pharming Group NV, Chief Executive Officer of Lycera Corporationration, Senior Vice President, Integrated Care at Sanofi, Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries Ltd., has held positions in small biopharmaceutical companies, large and small pharmaceutical companies and VCprivate equity firms, including TPG, Cerimon Pharmaceuticals, Ariad Pharmaceuticals and Novartis AG
Age: 60  Chairman Since 2017      
(972) 3 765 8555
Sekhri has over 30 years of operational experience in the life sciences sector with indepth knowledge of multinational pharmaceutical and biotechnology markets and products. He holds a BS degree in Zoology from University of Maryland and has completed postgraduate studies in Clinical Anatomy and Neuroscience at School of Medicine, University of Maryland.

Paul Sekhri Latest Insider Activity

COMPUGEN Management Efficiency

COMPUGEN has return on total asset (ROA) of (55.1606) % which means that it has lost $55.1606 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (1.0E-4) % meaning that it generated substantial loss on money invested by shareholders. COMPUGEN management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. As of June 5, 2020, Return on Investment is expected to decline to -86.62. The current year Return on Average Assets is expected to grow to -0.55COMPUGEN Total Assets are expected to significantly increase based on the last few years of reporting. The last year's Total Assets were at 53.76 Million. The current year Current Assets is expected to grow to about 91 M, whereas Return on Average Assets are expected to grow to (0.55) . The current year Current Liabilities is expected to grow to about 6.9 M, whereas Total Liabilities is expected to decline to about 13.2 M.
The company has accumulated 3.31 M in total debt with debt to equity ratio (D/E) of 0.03 which may suggest the company is not taking enough advantage from borrowing. COMPUGEN has Current Ratio of 7.05 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Company Summary

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 61 people.COMPUGEN (CGEN) is traded on Tel Aviv Stock Exchange in Israel and employs 61 people.

COMPUGEN Leadership Team

Joshua Shemer, Independent External Director
Michal Preminger, Director
Paul Sekhri, Chairman of the Board
Dov Hershberg, Director
Martin Gerstel, Chairman of the Board
Arie Ovadia, Independent External Director
Zurit Levine, Vice President - Research and Discovery
Eran Perry, Director
Ari Krashin, Chief Financial Officer
Sanford Zweifach, Director
Gilead Halevy, Director
Anat CohenDayag, President, Chief Executive Officer, Director
Ruth Arnon, Independent Director
Kinneret Savitsky, Director
Henry Adewoye, Chief Medical Officer
Yair Aharonowitz, Independent External Director
JeanPierre Bizzari, Director
John Hunter, VP of Antibody RandD and Site Head of Compugen USA Inc

Stock Performance Indicators

Did you try this?

Run Companies Directory Now


Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module

COMPUGEN Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for COMPUGEN and EVOGENE LTD. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page